Deal Making

Featured on Deal Making

Novo Nordisk to convert Purdue NC plant to make oral diabetes drug
Facilities & Capacity
Novo Nordisk to convert Purdue NC plant to make oral diabetes drugNovo Nordisk to convert Purdue NC plant to make oral diabetes drug

Novo Nordisk will rebuild a facility in Treyburn, North Carolina acquired from Purdue Pharma to support an oral form of its GLP-1 analogue semaglutide.

byDan Stanton, Editorial director
Aug 5, 2019
|
2 Min Read
Challenging the vaccine space: The problem with pioneers
Global Markets
Challenging the vaccine space: The problem with pioneersChallenging the vaccine space: The problem with pioneers
byBPI Staff
Aug 1, 2019
3 Min Read
Danaher: ‘All indications show GE is in wonderful shape’
Upstream & Downstream Processing
Danaher: ‘All indications show GE is in wonderful shape’Danaher: ‘All indications show GE is in wonderful shape’
byDan Stanton
Jul 31, 2019
2 Min Read
Big Pharma M&A a boon for business, says Thermo Fisher
Global Markets
Big Pharma M&A a boon for business, says Thermo FisherBig Pharma M&A a boon for business, says Thermo Fisher
byDan Stanton
Jul 30, 2019
2 Min Read
VGXI to supply plasmid for Geneos’ cancer DNA vaccines
Deal-Making
VGXI to supply plasmid for Geneos’ cancer DNA vaccinesVGXI to supply plasmid for Geneos’ cancer DNA vaccines
byDan Stanton
Jul 23, 2019
2 Min Read
Pall to provide ‘A-Z of single-use tech’ in Servier deal
Upstream & Downstream Processing
Pall to provide ‘A-Z of single-use tech’ in Servier dealPall to provide ‘A-Z of single-use tech’ in Servier deal
byDan Stanton
Jul 19, 2019
2 Min Read

More from Deal Making

Boehringer to buy cancer vaccine firm AMAL for €325m
Deal-Making
Boehringer to buy cancer vaccine firm AMAL for €325m
Boehringer to buy cancer vaccine firm AMAL for €325m
Jul 16, 2019
|
2 Min Read
byBPI Staff
Rights of Passage: Paragon building dedicated gene therapy suite
Facilities & Capacity
Rights of Passage: Paragon building dedicated gene therapy suite
Rights of Passage: Paragon building dedicated gene therapy suite
Jul 12, 2019
|
2 Min Read
byDan Stanton, Editorial director
Instrumental deal: Agilent to bolster cell analysis biz with BioTek buy
Deal-Making
Instrumental deal: Agilent to bolster cell analysis biz with BioTek buy
Instrumental deal: Agilent to bolster cell analysis biz with BioTek buy
Jul 12, 2019
|
2 Min Read
byDan Stanton, Editorial director
Investment digest: News from Pfizer, Bayer and Altimmune
Deal-Making
Investment digest: News from Pfizer, Bayer and Altimmune
Investment digest: News from Pfizer, Bayer and Altimmune
Jul 10, 2019
|
2 Min Read
byBPI Staff
M&A hungry BioLife to buy cold-chain services firm SAVSU
Deal-Making
M&A hungry BioLife to buy cold-chain services firm SAVSU
M&A hungry BioLife to buy cold-chain services firm SAVSU
Jul 9, 2019
|
2 Min Read
byDan Stanton, Editorial director
Ohr pushes for oligonucleotide merger with NeuBase
Deal-Making
Ohr pushes for oligonucleotide merger with NeuBase
Ohr pushes for oligonucleotide merger with NeuBase
Jul 5, 2019
|
2 Min Read
byBPI Staff
Lonza takes parenteral control through Novartis plant buy and contract
Facilities & Capacity
Lonza takes parenteral control through Novartis plant buy and contract
Lonza takes parenteral control through Novartis plant buy and contract
Jul 2, 2019
|
2 Min Read
byDan Stanton, Editorial director
Amicus contracts Thermo Fisher to make Batten disease gene therapy
Deal-Making
Amicus contracts Thermo Fisher to make Batten disease gene therapy
Amicus contracts Thermo Fisher to make Batten disease gene therapy
Jul 2, 2019
|
2 Min Read
byBPI Staff
AbbVie: Lack of Botox biosimilars a factor in $63bn Allergan buy
Therapeutic Class
AbbVie: Lack of Botox biosimilars a factor in $63bn Allergan buy
AbbVie: Lack of Botox biosimilars a factor in $63bn Allergan buy
Jul 1, 2019
|
3 Min Read
byDan Stanton, Editorial director
$63bn Allergan deal: ‘Humira is buying the assets that will replace it’
Deal-Making
$63bn Allergan deal: ‘Humira is buying the assets that will replace it’
$63bn Allergan deal: ‘Humira is buying the assets that will replace it’
Jun 26, 2019
|
3 Min Read
byDan Stanton, Editorial director
Eli Lilly on R&D: Two thirds internal, one third external
Deal-Making
Eli Lilly on R&D: Two thirds internal, one third external
Eli Lilly on R&D: Two thirds internal, one third external
Jun 21, 2019
|
2 Min Read
byDan Stanton, Editorial director
Biotech money: Global funding down despite spate of IPOs
Global Markets
Biotech money: Global funding down despite spate of IPOs
Biotech money: Global funding down despite spate of IPOs
Jun 21, 2019
|
2 Min Read
byBPI Staff
Celgene pays BeiGene $150m as it hands back anti-PD-1 rights
Deal-Making
Celgene pays BeiGene $150m as it hands back anti-PD-1 rights
Celgene pays BeiGene $150m as it hands back anti-PD-1 rights
Jun 19, 2019
|
2 Min Read
byDan Stanton, Editorial director
Alpine inks iPSCs vision lost therapy deal with Allele
Deal-Making
Alpine inks iPSCs vision lost therapy deal with Allele
Alpine inks iPSCs vision lost therapy deal with Allele
Jun 18, 2019
|
2 Min Read
byDan Stanton, Editorial director
Amgen: ‘We’ve shaved 3 years off development but can do better’
Global Markets
Amgen: ‘We’ve shaved 3 years off development but can do better’
Amgen: ‘We’ve shaved 3 years off development but can do better’
Jun 17, 2019
|
2 Min Read
byDan Stanton, Editorial director
Servier selects Yposkesi for viral vector supply
Deal-Making
Servier selects Yposkesi for viral vector supply
Servier selects Yposkesi for viral vector supply
Jun 11, 2019
|
2 Min Read
byDan Stanton, Editorial director
Merck in $773m deal to add preclinical MAb firm Tilos
Deal-Making
Merck in $773m deal to add preclinical MAb firm Tilos
Merck in $773m deal to add preclinical MAb firm Tilos
Jun 11, 2019
|
1 Min Read
byBPI Staff
Rexgenero adds CMO to speed up cell therapy trials
Deal-Making
Rexgenero adds CMO to speed up cell therapy trials
Rexgenero adds CMO to speed up cell therapy trials
Jun 4, 2019
|
2 Min Read
byDan Stanton, Editorial director
PE to boost Vibalogics’ viral vector capabilities
Deal-Making
PE to boost Vibalogics’ viral vector capabilities
PE to boost Vibalogics’ viral vector capabilities
Jun 2, 2019
|
2 Min Read
byDan Stanton, Editorial director
Affibody contracts 3P for psoriasis protein scale-up
Deal-Making
Affibody contracts 3P for psoriasis protein scale-up
Affibody contracts 3P for psoriasis protein scale-up
Jun 2, 2019
|
2 Min Read
byBPI Staff
Zolgensma approval marks success for REGENXBIO’s vector platform
Therapeutic Class
Zolgensma approval marks success for REGENXBIO’s vector platform
Zolgensma approval marks success for REGENXBIO’s vector platform
May 29, 2019
|
2 Min Read
byDan Stanton, Editorial director
Novartis to end $300m a year facility services deal with ISS
Deal-Making
Novartis to end $300m a year facility services deal with ISS
Novartis to end $300m a year facility services deal with ISS
May 28, 2019
|
1 Min Read
byBPI Staff
ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines
Bioprocess Insider
ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines
ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines
May 24, 2019
|
2 Min Read
byDan Stanton, Editorial director
WuXi scouts single-use site for Chinese vaccine joint venture
Global Markets
WuXi scouts single-use site for Chinese vaccine joint venture
WuXi scouts single-use site for Chinese vaccine joint venture
May 22, 2019
|
2 Min Read
byDan Stanton, Editorial director
Evotec lays down $90m to buy Just for kickstarting biologics biz
Deal-Making
Evotec lays down $90m to buy Just for kickstarting biologics biz
Evotec lays down $90m to buy Just for kickstarting biologics biz
May 21, 2019
|
2 Min Read
byBPI Staff
Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site
Deal-Making
Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site
Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site
May 17, 2019
|
2 Min Read
byDan Stanton, Editorial director
CDMO round-up: News from Patheon, Samsung and Sekisui
Deal-Making
CDMO round-up: News from Patheon, Samsung and Sekisui
CDMO round-up: News from Patheon, Samsung and Sekisui
May 15, 2019
|
3 Min Read
byBPI Staff
Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform
Deal-Making
Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform
Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform
May 15, 2019
|
3 Min Read
byDan Stanton, Editorial director
Subcutaneous success a boon for Halozyme, but biosimilars hit royalties
Global Markets
Subcutaneous success a boon for Halozyme, but biosimilars hit royalties
Subcutaneous success a boon for Halozyme, but biosimilars hit royalties
May 10, 2019
|
3 Min Read
byDan Stanton, Editorial director
Bayer plans $150m Californian biologics plant, creating 100 jobs
Deal-Making
Bayer plans $150m Californian biologics plant, creating 100 jobs
Bayer plans $150m Californian biologics plant, creating 100 jobs
May 10, 2019
|
2 Min Read
byDan Stanton, Editorial director

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Big Impact from Small Samples: Harnessing High-Precision Tunable Laser Spectroscopy for Complex Bioprocessing Analysis
Register Now: Big Impact from Small Samples: Harnessing High-Precision Tunable Laser Spectroscopy for Complex Bioprocessing Analysis
Ask the Expert webcasts
ATE Webcasts
Register Now: Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics
Register Now: Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics
Insider News
See all
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More

Innovative Technology

Nagase Trehalose SG
Sponsored Content
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG

Jan 9, 2025

Bruker Tornado Spectroscopy
Sponsored Content
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy

Dec 1, 2024

Thermo Fisher White Paper
Sponsored Content
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies

Nov 21, 2024

Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
Subscribe